Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by Kirtapmlaon Jun 28, 2016 7:22am

122 Views

Post# 25003810

RE:RE:RE:Sirona-the company has a lot of good directers

Hi,

Licence agreement for 1067 or a buyout of the 1067 or a buyout of the whole company is still peanuts for a large player as Allergan. As soon as they close the deal with Teva, (expected in June) Allergan will have 33,75 billion USD in cash to invest with. For me it doesn't make any sence for them only to do a license deal if they believe in our product.

If Allergan is the potential partner for Sirona why wouldn't they have already done the licence deal if this was the intention from their side? They could easily pay the 90MUSD for the upfront payment and dont have to wait until the deal with Teva is done.

Exiting times ahead!

Bullboard Posts

Stockhouse DealRoom opens new Australian opportunities